Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Protocol approach 1: immune rebalancing (thymosin alpha-1 plus KPV) Goal: Restore regulatory immune function while reducing inflammatory signaling Components: Thymosin alpha-1: 1.6 mg subcutaneously twice per week (promotes Treg expansion, modulates dendritic cells) KPV: 200-500 mcg daily, orally or subcutaneously (inhibits NF-kB, reduces TNF-alpha and IL-6) Rationale: Thymosin alpha-1 works at the cellular level to rebuild the regulatory arm of the immune system, while KPV addresses the inflammatory signaling that drives acute symptoms
Physical symptoms like muscle weakness or tingling in extremities (if present) may start to improve
Wolverine Stack Regulatory Status (June 2026) Neither BPC-157 nor TB-500 is FDA-approved as of June 2026
The "Units on U-100" column shows what that dose draws on a standard 1 mL insulin syringe
Mass spectrometry (MS) confirmation is a secondary but important quality indicator
Start improving your recovery today
